Aims and scope
DARU Journal of Pharmaceutical Sciences is an open access, peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment. The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.
All articles published by DARU Journal of Pharmaceutical Sciences are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in DARU Journal of Pharmaceutical Sciences you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. DARU Journal of Pharmaceutical Sciences therefore levies an article-processing charge of €850 for each article accepted for publication. The journal is supported by Tehran University of Medical Sciences (TUMS).
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
Note for Iran-based authors
For authors based in Iran a discounted APC of €700 and a special mechanism for covering the APC apply. Iran-based authors should enter the code DARU01 during the article submission process. If this code is used, Iran-based authors do not pay an APC to the publisher; instead, TUMS arranges payments with the publisher and will invoice the APC, payable in Iranian Rials, to the authors.
All articles published in DARU Journal of Pharmaceutical Sciences are included in:
- Biological Abstracts
- Global Health
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
DARU Journal of Pharmaceutical Sciences has an Impact Factor of 1.653.
Peer review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
DARU Journal of Pharmaceutical Sciences operates a double-blind peer-review system, where the reviewers do not know the names or affiliations of the authors and the reviewer reports provided to the authors are anonymous.
The benefit of double-blind peer review is that it allows reviewers to judge the manuscript based on content alone, and they are not unconsciously biased by knowledge of who the authors are.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to DARU Journal of Pharmaceutical Sciences should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in DARU Journal of Pharmaceutical Sciences
Articles in DARU Journal of Pharmaceutical Sciences should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. DARU [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. DARU 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in DARU Journal of Pharmaceutical Sciences
DARU Journal of Pharmaceutical Sciences's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
DARU Journal of Pharmaceutical Sciences offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in DARU Journal of Pharmaceutical Sciences gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in DARU Journal of Pharmaceutical Sciences are included in article alerts and regular email updates. Some may be highlighted on DARU Journal of Pharmaceutical Sciences’s pages and on the BioMed Central homepage.
In addition, articles published in DARU Journal of Pharmaceutical Sciences may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in DARU Journal of Pharmaceutical Sciences. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in DARU Journal of Pharmaceutical Sciences you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.